Skip to main content

Table 2 Procedural characteristics and angiographic outcomes

From: Five-year clinical outcomes in patients with diabetes mellitus treated with polymer-free sirolimus- and probucol-eluting stents versus second-generation zotarolimus-eluting stents: a subgroup analysis of a randomized controlled trial

Lesion-level characteristics Sirolimus- and probucol-eluting stent (n = 849) Zotarolimus-eluting stent (n = 439) P value
Balloon diameter (mm) 3.05 (2.59–3.47) 3.02 (2.60–3.45) 0.82
Stented length (mm) 25 (18–34) 24 (18–33) 0.23
In stent analysis
Post-procedural minimal luminal diameter (mm) 2.50 ± 0.50 2.57 ± 0.49 0.045
Post-procedural percent diameter stenosis (%) 12 ± 7 11 ± 7 0.03
At follow-up minimal luminal diameter (mm)a 2.13 ± 0.73 2.20 ± 0.72 0.18
At follow-up percent diameter stenosis (%)a 24 ± 22 23 ± 21 0.68
Late lumen loss (mm)a 0.36 ± 0.63 0.36 ± 0.59 0.48
In segment analysis
Post-procedural minimal luminal diameter (mm) 2.23 ± 0.58 2.26 ± 0.55 0.33
Post-procedural percent diameter stenosis (%) 22 ± 12 22 ± 12 0.83
At follow-up minimal luminal diameter (mm)a 1.90 ± 0.70 1.98 ± 0.69 0.10
At follow-up percent diameter stenosis (%)a 33 ± 20 32 ± 19 0.20
Late lumen loss (mm)a 0.31 ± 0.61 0.26 ± 0.57 0.34
Binary restenosisa 107 (17.0) 57 (17.2) 0.95
  1. Data shown as mean ± SD or median (25th–75th percentiles) or n (%)
  2. aData available for 961 lesions (74.6 %)